IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)

• ClinicalTrials.gov Identifier: NCT02193347
• Recruitment Status: Active, not recruiting
• First Posted: July 17, 2014
• Results First Posted: March 15, 2021
• Last Update Posted: March 15, 2021
• Sponsor: Gary Archer Ph.D.
• Information provided by (Responsible Party): Gary Archer Ph.D., Duke University

Study Description

Brief Summary:

Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy (temozolomide).

Condition or disease	Intervention/treatment	Phase
Brain Cancer; Brain Neoplasm, Primary; Brain Neoplasms, Recurrent; Brain Tumor; Cancer of the Brain	Biological: PEPIDH1M vaccine; Biological: Tetanus-Diphtheria Toxoid (Td); Drug: Temozolomide	Phase 1

Detailed Description:

After informed consent has been signed, subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen.

Eligible subjects will undergo a 1-2 hour leukapheresis (to pull off white blood cells) for immune monitoring. Within 48 hours of leukapheresis, subjects will receive vaccine site pre-conditioning as a single dose of Td toxoid (in a total volume of 0.4 mLs salt water/saline) given in the intradermal space (just under the surface of the skin) to the right groin area. The pre-conditioning will be administered one day prior to receiving PEPIDH1M vaccine. The peptide vaccine is administered in the upper thigh area approximately 4 inches below the groin in the intradermal space as vaccine # 1. Subsequent vaccines will be given on day 15 ±3 days (vaccine #2) and day 29 ±3 days (vaccine #3). Each injection of the peptide vaccine will be given half on the right groin and half on the left groin. The first 3 peptide vaccine injections will occur without temozolomide (standard of care chemotherapy).

Seven to twelve days after the 3rd vaccine, subjects will have standard of care surgery to remove the tumor. Tumor samples will be evaluated for the IDH1 markers and analyzed for other cells that may have entered the tumor.

Based on the the tissue obtained at surgery, subjects with stable histologic grade at recurrence will then be treated with vaccine and temozolomide. During monthly cycles of temozolomide, subjects will receive the vaccine on day 22 (+ 2 days) for a maximum of 15 total vaccines (which includes the first 3 bi-weekly vaccines). Patients that have transitioned to a higher grade brain tumor at the time of surgery will receive temozolomide and radiation therapy per standard of care and monthly vaccines (vaccines #4-6). After completion of radiation therapy, subjects in this treatment group will receive vaccines monthly on day 22 (+2 days) with post-RT cycles of TMZ to a maximum of 15 vaccines.

All Adverse Events will be collected from time of consent until off study. The treatment phase of the study will end 1 month after the last vaccine. Patients will be followed only for overall survival, progression-free survival, and subsequent therapies thereafter.

Subjects will have blood collected for immune monitoring and biomarker testing during the following times: prior to initiating vaccine therapy (at the leukapheresis visit), prior to surgery to remove the tumor, at the clinic visit prior to starting first cycle of temozolomide after surgery (or radiation therapy and temozolomide for those who transition to higher grade), at vaccine #6, and at end of vaccine treatment (1 month after vaccine #15 or time the subject comes off study, whichever comes first).

Subjects will be imaged with contrast-enhanced magnetic resonance imaging (MRI) according to standard of care every 10 weeks (+/- 4 weeks) while on temozolomide and afterward, per the treating neuro-oncologist's recommendation. Revised Assessment in Neuro-Oncology (RANO) criteria will be used for assessment of pseudoprogression and tumor progression. Subjects demonstrating definitive progression will be removed from study.

As part of standard care for these subjects, upon tumor progression, participants may undergo biopsy or resection. As this is not a research procedure, consent will be obtained separately. Subjects that have this procedure done within the Duke University Health System will be asked to have a portion of the tumor sample, if possible, to assess immunologic cell infiltration, antigen expression, and biomarkers for immunologic response.

Please note, data collection will continue to occur outside of the defined primary and secondary outcomes for exploratory objectives.

The specific exploratory objective involves describing the progression free survival (PFS) and overall survival (OS). The endpoint is the proportion of patients alive without disease progression 6 months after initial vaccine treatment, and both the median PFS, and the median OS.

The objective will be reviewed at 3 years after the last subject came off study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 24 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
• Actual Study Start Date: January 28, 2016
• Actual Primary Completion Date: February 3, 2020
• Estimated Study Completion Date: December 2022

Arms and Interventions

Arm

Intervention/treatment

Experimental: PEPIDH1M vaccine; PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.

Biological: PEPIDH1M vaccine; PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.; Biological: Tetanus-Diphtheria Toxoid (Td); After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.; Other Name: Tenivac; Drug: Temozolomide; Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.; Other Name: Temodar

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants With an Unacceptable Toxicity [ Time Frame: Date of consent through 2 months after the last vaccination ]
   The percentage of patients who experience an unacceptable toxicity defined as any Grade 3 toxicity at least possibly attributed to the vaccine (or vaccine + TMZ and/or RT) that does not resolve to baseline within 3 weeks, any Grade 3 hypersensitivity reactions requiring steroids, any Grade 4 toxicity, including neurologic events not due to progressive disease, or any life threatening-event not attributable to concomitant medication, co-morbid event, or disease progression.

Secondary Outcome Measures :

1. Percentage of Evaluable Subjects Who Had a Response Greater Than 20 Spot-forming Cells (SFC) Per 10^6 Lymphocytes [ Time Frame: From time of pheresis #1, one day prior to first pre-surgery vaccine dose, until the time of the third post-surgery vaccination, an expected average of 24 weeks after study initiation ]
   The number of spot-forming cells (SFC) per 10^6 lymphocytes measured by ELISpot. A blue-black colored precipitate forms and appears as spots at the sites of cytokine localization, with each individual spot representing an individual analyte-secreting cell.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age ≥ 18 years.
2. IDH1R132H expression in primary tumor
3. Radiographic and/or clinical progressive and resectable Grade II glioma.
4. Signed informed consent.
5. For females of child-bearing potential, negative serum pregnancy test at screening (within 48 hours prior to leukapheresis)
6. Women of childbearing potential and male participants must agree to practice adequate contraception.
7. Karnofsky Performance Status (KPS) of ≥ 70.

8. Complete Blood Count (CBC)/differential with adequate bone marrow function as defined below within 2 weeks of enrollment:

   • Absolute neutrophil count, ≥ 1500 cells/mm3.
   • Platelet count, ≥ 100,000 cells/mm3.
   • Hemoglobin ≥ 10 g/dl. (Note: the use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)

9. Adequate renal function as defined below within 2 weeks of enrollment:

   • Blood Urea Nitrogen (BUN) ≤ 25 mg/dl.
   • Creatinine ≤ 1.7 mg/dl.

10. Adequate hepatic function as defined below within 2 weeks of enrollment:

    • Bilirubin ≤ 2.0 mg/dl.
    • Alanine Aminotransferase (ALT) ≤ 3 x normal range.
    • Aspartate Aminotransferase (AST) ≤ 3 x normal range

Exclusion Criteria:

1. Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years. (For example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible.)
2. Metastases detected below the tentorium or beyond the cranial vault.

3. Severe, active co-morbidity, defined as follows:

   • Unstable angina and/or congestive heart failure requiring hospitalization.
   • Myocardial infarction within the last 6 months.
   • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because treatments involved in this protocol may be significantly immunosuppressive.
   • Major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.
4. Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug.
5. Prior allergic reaction to temozolomide.
6. Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study.
7. Patients with known hypersensitivity to GM-CSF, yeast-derived products, or any component of Leukine®.
8. Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine.
9. Unable to undergo MRI imaging.

Contacts and Locations

Locations

United States, North Carolina

Duke University Medical Center

Durham, North Carolina, United States, 27710

Sponsors and Collaborators

Gary Archer Ph.D.

Investigators

• Principal Investigator: Katherine Peters, M.D., Ph.D.; Duke University

  Study Documents (Full-Text)

Documents provided by Gary Archer Ph.D., Duke University:

Study Protocol and Statistical Analysis Plan  [PDF] October 11, 2017

More Information

• Responsible Party: Gary Archer Ph.D., Assistant Professor Neurosurgery, Duke University
• ClinicalTrials.gov Identifier: NCT02193347
• Other Study ID Numbers: Pro00054746
• First Posted: July 17, 2014
• Results First Posted: March 15, 2021
• Last Update Posted: March 15, 2021
• Last Verified: February 2021

Keywords provided by Gary Archer Ph.D., Duke University:

Immunotherapy; Adult

Additional relevant MeSH terms:

Neoplasms; Brain Neoplasms; Recurrence; Disease Attributes; Pathologic Processes; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Temozolomide; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents